{
    "clinical_study": {
        "@rank": "156198", 
        "arm_group": [
            {
                "arm_group_label": "S1 generic", 
                "arm_group_type": "Experimental", 
                "description": "40mg\uff0fm2 bid four weeks on two weeks off"
            }, 
            {
                "arm_group_label": "capecitabine", 
                "arm_group_type": "Active Comparator", 
                "description": "2500mg\uff0fm2\uff0fday divided into twice two weeks on one week off"
            }
        ], 
        "brief_summary": {
            "textblock": "Comparing S1 generic With Capecitabine in Patients With Metastatic Breast Cancer."
        }, 
        "brief_title": "A Trial Comparing S1 Generic With Capecitabine in Metastatic Breast Cancer (MBC)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Metastatic Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Comparing S1 generic(Tegafur\uff0cGimeracil and Oteracil Potassium Capsules) With Capecitabine in\n      Patients With Metastatic Breast Cancer."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed breast cancer\n\n          -  Pretreated metastatic breast cancer not more than 2 lines chemotherapy\n\n          -  Have not been previously treated with capecitabine,oral fluracil\n\n          -  ECOG performance status of \u2264 1\n\n          -  Be female and \u2265 18 and \u2264 75 years of age\n\n          -  Have at least one target lesion according to the RECIST criteria 1.1\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women\n\n          -  ECOG \u2265 2\n\n          -  Have been treated with capecitabine\n\n          -  Evidence of CNS metastasis\n\n          -  History of another malignancy within the last five years except cured basal cell\n             carcinoma of skin and carcinoma in-situ of uterine cervix or a contralateral breast\n             cancer\n\n          -  Abnormal laboratory values: hemoglobin < 10.0 g/dl, absolute neutrophil count <\n             1.5\u00d710^9/L, platelet count < 100\u00d710^9/L, serum creatinine > upper limit of normal\n             (ULN), serum bilirubin > ULN, ALT and AST > 5\u00d7ULN, AKP > 5\u00d7ULN\n\n          -  Serious uncontrolled intercurrent infection\n\n          -  Life expectancy of less than 3 months"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "386", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 27, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655992", 
            "org_study_id": "Fudan BR2012-09 CBCSG010"
        }, 
        "intervention": [
            {
                "arm_group_label": "capecitabine", 
                "description": "2500mg\uff0fm2\uff0fday divided into twice two weeks on one week off", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug", 
                "other_name": "Xeloda"
            }, 
            {
                "arm_group_label": "S1 generic", 
                "description": "40mg\uff0fm2 bid four weeks on two weeks off", 
                "intervention_name": "S1 generic", 
                "intervention_type": "Drug", 
                "other_name": "Tegafur\uff0cGimeracil and Oteracil Potassium Capsules"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tegafur", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "capecitabine", 
            "Tegafur\uff0cGimeracil and Oteracil Potassium Capsules"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Shanghai", 
                    "country": "China", 
                    "state": "Shanghai", 
                    "zip": "200032"
                }, 
                "name": "Fudan University Cancer Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Open Label Multicenter Phase 3 Trial Comparing S1 Generic With Capecitabine in Patients With Metastatic Breast Cancer.", 
        "overall_official": {
            "affiliation": "Fudan Univeristy Cancer Hospital", 
            "last_name": "Xi-chun Hu, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "progression free survival", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655992"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fudan University", 
            "investigator_full_name": "Xichun Hu", 
            "investigator_title": "Vice Director of department of medical oncology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "response rate", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 months"
            }, 
            {
                "measure": "overall survival", 
                "safety_issue": "Yes", 
                "time_frame": "12 months"
            }
        ], 
        "source": "Fudan University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fudan University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}